header logo image

Replimune to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

May 24th, 2024 2:52 am

WOBURN, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- Replimune Group Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of oncolytic immunotherapies, today announced multiple presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago from May 31-June 4, 2024.

Read the original post:
Replimune to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Related Post

Tags:

Comments are closed.


2024 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick